Pim1 kinase regulates c-Kit gene translation

Ningfei An¹, Bo Cen², Houjian Cai³, Jin H. Song⁴, Andrew Kraft⁴ and Yubin Kang⁵*

Abstract

Background: Receptor tyrosine kinase, c-Kit (CD117) plays a pivotal role in the maintenance and expansion of hematopoietic stem/progenitor cells (HSPCs). Additionally, over-expression and/or mutational activation of c-Kit have been implicated in numerous malignant diseases including acute myeloid leukemia. However, the translational regulation of c-Kit expression remains largely unknown.

Methods and results: We demonstrated that loss of Pim1 led to specific down-regulation of c-Kit expression in HSPCs of Pim1⁻/⁻ mice and Pim1⁻/⁻/2⁻/⁻/3⁻/⁻ triple knockout (TKO) mice, and resulted in attenuated ERK and STAT3 signaling in response to stimulation with stem cell factor. Transduction of c-Kit restored the defects in colony forming capacity seen in HSPCs from Pim1⁻/⁻ and TKO mice. Pharmacologic inhibition and genetic modification studies using human megakaryoblastic leukemia cells confirmed the regulation of c-Kit expression by Pim1 kinase: i.e., Pim1-specific shRNA knockdown down-regulated the expression of c-Kit whereas overexpression of Pim1 up-regulated the expression of c-Kit. Mechanistically, inhibition or knockout of Pim1 kinase did not affect the transcription of c-Kit gene. Pim1 kinase enhanced c-Kit 35S methionine labeling and increased the incorporation of c-Kit mRNAs into the polysomes and monosomes, demonstrating that Pim1 kinase regulates c-Kit expression at the translational level.

Conclusions: Our study provides the first evidence that Pim1 regulates c-Kit gene translation and has important implications in hematopoietic stem cell transplantation and cancer treatment.

Keywords: Receptor tyrosine kinase, c-Kit, PIM kinase, Serine/threonine kinase, Translation, Regulation, Hematopoiesis, Hematopoietic stem cells, Hematopoietic progenitor cells

Background

c-Kit receptor (CD117), a member of the type III transmembrane receptor tyrosine kinase (RTK) family, plays an essential role in fetal and adult hematopoiesis [1–3]. When binding to its ligand, stem cell factor (SCF), c-Kit receptor dimerizes and phosphorylates at tyrosine residues, leading to the activation of the mitogen activated protein (MAP) kinase cascade (cRaf/Mek/Erk), the JAK/STAT pathway, and the phosphoinositide-3 (PI-3) kinase signaling events [4]. Additionally, overexpression or activating mutation of c-Kit is implicated in the pathogenesis of many human cancers including acute myeloid leukemia (AML) [5–7]. Because of the important roles of c-Kit in many physiological and pathological processes, there have been extensive studies undertaken to understand its transcriptional regulation, signal pathways, receptor dimerization, and protein degradation [8–11]. However, currently very little is known about the translational regulation of c-Kit.

Proviral insertion in murine lymphoma (Pim) kinases are a small family of serine/threonine kinases, and have 3 isoforms (Pim1, Pim2, and Pim3) [12–15]. Pim kinases are oncogenic in several hematological malignancies including acute leukemia and lymphoma [12–15]. Furthermore, Pim kinases are involved in the regulation of hematopoiesis [16–18]. We have recently demonstrated that Pim1 kinase regulates the biologic function and number of murine HSPCs [17, 18]. How Pim1 regulates murine hematopoiesis remains to be determined. Herein we reported the role and the molecular mechanisms of
Pim1 in regulating c-Kit expression in murine HSPCs and in human leukemia cells.

Methods

Cell lines

Human megakaryoblastic leukemia Molm-16 cells were grown in RPMI1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Human embryonic kidney (HEK) 293 cells were grown in DMEM high glucose medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. All the cells were cultured at 37 °C with 5% CO₂.

Mice

Pim single knockout (KO) mice (Pim1−/−, Pim2−/−, and Pim3−/− mice), Pim triple (Pim1−/−Pim2−/−Pim3−/−) KO mice (TKO), and Pim1 transgenic (Pim1-Tx) mice have been described previously [17, 18]. All our animal studies were performed at Medical University of South Carolina (MUSC) and were in accordance with MUSC Institutional Animal Care and Use Committee approved procedures.

Antibodies

Antibodies used for flow cytometry analyses, i.e., APC-conjugated anti-mouse c-Kit (CD117) antibody (2B8), PE-conjugated anti-mouse Sca-1 antibody (E13-161.7), PE-conjugated anti-human c-Kit antibody (YB5.B8), APC-conjugated anti-human c-Kit antibody (YB5.B8), phospho-ERK antibody (Thr202/Tyr204), and phospho-STAT3 antibody (pY705) were purchased from BD Pharmingen (San Diego, CA). Antibodies used for immunoblot analyses, i.e., anti-c-Kit antibody (D13A2), anti-phospho-S6 antibody, anti-phospho-ERK antibody, elf4B antibody, phospho-elf4B (Ser406) antibody, and phospho-elf4B (Ser422) antibody were obtained from Cell signaling (Beverly, MA). Anti-β-Actin antibodies were purchased from Sigma-Aldrich (St. Louis, MO).

Reagents

Murine recombinant stem cell factor (SCF), human recombinant SCF, and Aqua Live/dead fixable dye were purchased from Invitrogen (Grand Island, NY). Hoechst 33342 and hexadimethrine bromide (polybrene) were purchased from Sigma-Aldrich (St. Louis, MO). Magnetic murine lineage cell depletion kit was purchased from Miltenyi Biotec (Auburn, CA). Trans-Lentiviral shRNA Packaging Kit with Calcium Phosphate (TLP5913) was purchased from Thermo Scientific (Pittsburgh, PA). GNE568 (a Pim 1 and 3 inhibitor) and GNE652 (a pan Pim inhibitor) were kindly provided by Dr. Allen Ebens at Genenetech Inc. (San Francisco, CA). SGI-1776 and CX-6258, both of which are pan Pim inhibitors, were purchased from Selleckchem (Houston, TX).

Flow cytometry analysis

For the measurement of side population (SP) cells, bone marrow (BM) cells were harvested from the femurs and tibias of different genotypes of mice. Red blood cells (RBCs) were depleted using ACK lysis buffer. The RBC-depleted BM cells were enriched for Lin− cells using murine lineage cell depletion kit. Lin− cells were first labeled with c-Kit antibody and Scal-1 antibody and then stained with Hoechst 33342 dye as previously described [19]. Briefly, Hoechst 33342 at a final concentration of 5 µg/ml was added to the cells (10⁶ cells/ml), and the cells were incubated at 37 °C for 90 min. At the end of incubation, the cells were washed with PBS and analyzed within 2 h on MoFlo flow cytometer (Beckman).

For the measurement of c-Kit surface expression in cell lines after drug treatment or gene transfer, the cells were stained with human PE-conjugated c-Kit antibody or APC-conjugated c-Kit antibody followed by live/dead dye staining.

For phospho-flow analysis, a previously described method was used with modifications [20]. Briefly, BM Lin− cells were first starved in serum free RPMI1640 media for 30 min followed by 10 min stimulation with pre-warmed media containing SCF at a final concentration of 100 ng/ml for 10 min. The cells were then fixed in paraformaldehyde (a final concentration of 1.6%) for 10 min. The cells were processed for surface staining, permeabilization with acetone, and staining with phospho antibodies. All flow cytometry data were analyzed using FlowJo software (TreeStar, Inc., Ashland, OR, USA).

Lentivirus production and gene transduction

The production and gene transduction of lentiviruses encoding shRNA against human Pim-1 or control shRNA were performed as described previously [21]. For the production of lentiviral vector encoding murine c-Kit, the open reading frame of murine c-Kit was PCR-amplified from the parental vector, pcDNA3-c-Kit (a gift from Dr. Harrison’s lab) [22]. The primers were: c-kit-XbaI-F: 5’ TCGATCTAGAATGAGGCGCTCGCGGCGCTCTAGACGAGCGCAGGCT-3’, and c-kit-XbaI-R: 5’-GGGGTCTTAGATCAGGCATCTTCGTCACGAGCAGCAG-3’. The PCR product was subcloned into FU-CRW lentiviral vector [23]. The clones were sequenced and the clone with right c-Kit orientation was used for the lentiviral production and titer determination as described previously [24].

 Colony-forming unit (CFU) assay

Bone marrow CFU assays were performed as previously described [25]. BM cells were harvested from wildtype mice, Pim1−/− mice, Pim2−/− mice, or TKO mice. RBC-depleted BM cells were transduced with c-Kit FU-CRW or control FU-CRW lentiviruses by centrifugation at
3000×g for 90 min in the presence of 8 μg/ml polybrene. The cells were then plated in triplicates in complete M3434 methylcellulose medium (Stem Cell Technologies) following the manufacturer’s instructions (30,000 cells per well) on 6-well plates. The number of CFUs-GM, BFUs-E and CFUs-GEMM was counted at days 7, 9, and 12, respectively.

Western blot analysis
Following drug treatment or lentiviral transduction, cells (Molm-16 or HEK293 cells) were harvested, washed with PBS, and re-suspended in lysis buffer A containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% Sodium deoxycholate, and 0.1% SDS. The cells were further lysed by brief sonication. The lysates were centrifuged at high speed for 10 min to remove cell debris. Total protein was quantified using DC protein assay kit (Bio Rad) with BSA for standard curve. Approximately 20 μg protein was loaded and run on SDS PAGE. The proteins were transferred onto nitrocellulose membrane. The membrane was blocked with 5% milk in Tris-Buffered Saline containing 0.05% of Tween 20 (TBST) and primary antibodies were applied with 1% BSA in TBST for overnight at 4 °C with gentle rocking. The membrane was then probed with HRP-conjugated secondary antibody and developed using Pierce ECL substrate.

Polysome profiling and RT-PCR analysis
Human embryonic kidney 293T cell extracts used for polysome gradient centrifugation were prepared as previously described [26–28]. In brief, 5 × 10^6 HEK cells transduced with control lentiviral vector (HEK-Fu-Ctl) or Pim1-over-expressing lentivector (HEK-Fu-Pim1) were cultured in 10-mm culture dishes and harvested after replacing the culture media with fresh media containing cycloheximide (Sigma, 100 μg/ml) for 15 min. Cells were washed with PBS and then directly lysed in TMK100 buffer (10 mM Tris-HCl (pH 7.4), 100 mM KCl, 5 mM MgCl2, 1% (v/v) Triton X-100, 0.5% w/v deoxycholate, 2 mM dithiothreitol) on ice for 20 min. The lysates were centrifuged for 15 min at 10,000×g at 4 °C, and the supernatants were layered on top of linear 10–50% (w/v) sucrose gradients. Centrifugation was carried out in a Beckmann SW41Ti Rotor at 35,000 rpm for 3 h at 4 °C. Polysome profiles were monitored by absorbance at 254 nm (A254). RNA from each fraction was isolated by Trizol extraction. One-step RT-PCR was performed using the MyTaq™ One-Step RT-PCR Kit (Bioline) on an Eppendorf MasterCycler. All primers were designed and synthesized by Invitrogen.

35S methionine labeling assay
Human embryonic kidney 293T cells transduced with control lentiviruses or Pim1-overexpressing lentiviruses were labeled with 20 μCi of 35S methionine per ml (Easytag Express Protein Labeling Mix, PerkinElmer) in RPMI1640 without cold methionine for 1 h, washed twice with PBS, and lysed in lysis buffer A. Cell lysates were centrifuged at 13,000×g for 10 min. The supernatant was collected and immunoprecipitation was performed with c-Kit antibody. Immunoprecipitated proteins were resolved by SDS-polyacrylamide gel and processed on SDS gel. Newly synthesized 35S methionine-c-Kit was visualized after exposure to X-AR films and then analyzed by a liquid scintillator (Beckman 6500).

Statistical analysis
Values reported and shown in graphical displays are mean +/- standard error of the mean (SEM) except where noted. Comparisons of mean expression across groups were made using two-sample t-tests. p value < 0.05 was used to denote significance.

Results and discussion
We recently reported that Pim1, but not Pim2 or Pim3, plays a major role in the regulation of normal murine HPSC function [17, 18]. To determine the roles of Pim kinases in the regulation of c-Kit expression, we analyzed c-Kit level in lineage negative (Lin−) bone marrow (BM) cells isolated from age-matched wildtype (WT), Pim1−/−, Pim2−/−, Pim3−/−, Pim1−/−2−/−3−/− triple knockout (TKO) mice, and Pim1 transgenic mice (Pim1-Tx). Compared to WT Lin− BM cells, Lin− BM cells from Pim1−/− mice and Pim TKO mice showed a reduced level of c-Kit expression, whereas no changes in c-Kit expression were observed in Lin− BM cells from Pim2−/− or Pim3−/− mice (Fig. 1a). Conversely, Pim1-Tx mice showed an enhanced c-Kit expression (Fig. 1a). Additionally, c-Kit expression in murine hematopoietic stem cells (HSCs) defined by Hoechst 33342 side population (SP) showed similar changes [19]: i.e., compared to WT SP cells, the SP HSCs from Pim1−/− and Pim TKO mice had reduced levels of c-Kit expression, whereas no changes was observed in Pim2−/− SP cells (Fig. 1b). The effect of Pim1 on murine HSPC c-Kit expression is c-Kit-specific, because Pim1 deletion did not affect the expression of Sca-1 or Flt3 (a member of type III RTK family) in Lin− BM cells (Fig. 1c). Further supporting the reduction in c-Kit expression level, p-ERK and p-STAT3 following SCF stimulation were significantly decreased in the HSPCs isolated from Pim TKO mice compared to those from age-matched WT mice (Fig. 1d). Taken together, these data demonstrated an important role of Pim kinases, in
particular Pim1 kinase, in regulating c-Kit expression in murine HSPCs.

Hematopoietic stem/progenitor cells from Pim1\(^{-/-}\) and TKO mice had defects in CFUs as well as in their self-renewal and long-term repopulating capacity [17, 18]. To determine if the down-regulation of c-Kit expression contributes to the hematopoietic defects seen in these mice, we transduced BM cells from Pim1\(^{-/-}\) mice,
Pim2−/− mice, TKO mice or WT mice with c-Kit expressing lentiviral vector (Fu-c-Kit) or control vector (Fu-Ctl). CFUs were then measured. Transduction with c-Kit restored the impaired colony-forming ability (CFUs-GM, BFUs-E and CFUs-GEMM) seen with Pim1−/− mice and TKO mice (Fig. 2), indicating that Pim1 kinase regulates murine hematopoiesis at least in part through controlling c-Kit expression. Over-expression of c-Kit did not affect the CFUs in Pim2−/− cells (Fig. 2).

We next performed pharmacologic and genetic studies using leukemia cell lines to further validate the regulation of c-Kit by Pim1 kinase. Molm-16, a megakaryoblastic leukemia cell line was used because in our pilot screening this cell line was found to have high level of c-Kit expression (data not shown). We found that treatment with GNE568 (a Pim1 and Pim3 dual kinase inhibitor) or GNE652 (a pan-Pim kinase inhibitor) resulted in reduced level of c-Kit expression in Molm-16 cells by western immunoblot (Fig. 3a) and flow cytometry (Fig. 3b). Additionally, specific knockdown of Pim1 by shRNA led to reduced c-Kit expression (Fig. 3c), and completely blocked SCF-induced ERK phosphorylation (Fig. 3c, d). pS6, an indicator for mTOR pathway and a downstream target of Pim, was used to validate the effectiveness of Pim inhibition with shRNA. Furthermore, exogenous overexpression of Pim1 resulted in increased level of c-Kit expression in HEK293 T cells transfected with Pim1-overexpression plasmid (Fu-Pim-1) (Fig. 3e). These studies further demonstrated the regulation of c-Kit expression by Pim1 kinase.

We examined the mechanisms through which Pim1 kinase regulates c-Kit expression. No significant difference in c-Kit mRNA level was observed in BM cells derived from WT mice, Pim1−/− mice, TKO mice, and Pim1 Tx mice. Additionally, treatment with Pim inhibitors did not affect c-Kit mRNA level (data not shown), suggesting that Pim1 kinase does not regulate c-Kit expression at the transcriptional level. We then determined if c-Kit is translationally regulated by Pim1 kinase. To this end, we transfected HEK293T cells with Pim1-expressing plasmid or control plasmid and performed 35S methionine-labeling assay. As shown in Fig. 4a, over-expression of Pim1 increased 35S methionine labeled c-Kit level, suggesting that Pim1 kinase stimulates new c-Kit protein synthesis via enhanced translation. To further determine the effects of Pim1 on c-Kit gene translation, we fractioned ribosomes of HEK293 T cells transduced with control lentiviral vector (Fu-Ctl) or Pim1 overexpressing lentiviral vector (Fu-Pim1) and measured c-Kit RNA incorporation in polysomes and monosomes. As shown in Fig. 4b, more c-Kit RNA was seen in ribosomes of Pim1-transduced HEK293 T cells compared to those of control vector-transduced HEK293 T cells. Eukaryotic translation initiation factor 4B (eIF4B) plays an important role in the translation initiation [29]. When phosphorylated on Ser422, eIF4B enhances the binding of mRNA to the 43S preinitiation complex. To examine the effects of Pim inhibitors on the phosphorylation of eIF4B, we treated Molm-16 cells with 2 different pan-Pim inhibitors (SGI1776 and CX6528), and measured phosphorylated eIF4B at Ser406 or Ser422. As shown in Fig. 4c, Pim inhibition down-regulated the phosphorylated eIF4B (Ser422). Taken together, these data demonstrated that Pim1 kinase regulates c-Kit gene translation.
Conclusion

Our current study demonstrates an important role of Pim1 kinase in the regulation of c-Kit in murine HSPCs and in human megakaryoblastic leukemia cell line. Our results suggest that this regulation occurs at translation level. These data are consistent with recent findings that Pim1 kinase regulates gene translation of c-MET in prostate cancer [27] and PDGFR in prostate stromal fibroblasts [28]. Pim kinases have been shown to regulate translation through the phosphorylation of PRAS40 [30], TSC2 [31], and 4E-BP1 [32], leading to stimulation of mTOR activity and enhancing 5’Cap induced translation [33].

Our study has several important implications. Our findings provide new insight into the regulation of hematopoiesis. Furthermore, because of the important roles of Pim kinase in hematopoiesis, it is expected that Pim inhibitors will cause bone marrow suppression, and thus hematological parameters will need to be monitored closely during clinical trials using Pim inhibitors for cancer treatment [34]. On the other hand, c-Kit is over-expressed and plays an important role in...
the pathogenesis of leukemia and several other hematological malignancies. Targeting Pim kinases could be an effective treatment strategy for decreasing this receptor in conditions where it drives malignant growth.

Abbreviations
HSCs: hematopoietic stem cells; HSPCs: hematopoietic stem/progenitor cells; SP: side population; RTK: receptor tyrosine kinase; SCF: stem cell factor; AML: acute myeloid leukemia; Pim: proviral insertion in murine lymphoma; WT: wildtype; KO: knockout mice; TPO: Pim1<sup>−/−</sup>2<sup>−/−</sup>3<sup>−/−</sup> triple knockout mice; Lin−: lineage negative; BM: bone marrow; CFU: colony-forming unit.

Authors’ contributions
NA conceived, performed most of the experiments, analyzed data, contributed to the writing of the manuscript; BC and JHS assisted with vector construction, ribosome profiling and methionine labeling assay; HC performed c-Kit lentiviral production and contributed to the writing of the manuscript; AK provided animal colonies and contributed to the writing of the manuscript; YK conceived and designed the study and wrote the manuscript. All authors read and approved the final manuscript.

Author details
1 Department of Pathology, University of Chicago, Chicago, USA. 2 Hollings Cancer Center, Medical University of South Carolina, Charleston, USA. 3 Department of Pharmaceutical & Biomedical Sciences, University of Georgia, Athens, USA. 4 The University of Arizona Cancer Center, University of Arizona, Tucson, USA. 5 Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University, DUMC 3961, Durham, NC 27710, USA.

Acknowledgements
We thank Dr. Allen Ebens at Genentech Inc. for providing us reagents (GNE568 and GNE652) for our study.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets supporting the conclusion of this article are included within this article.

Ethics approval and consent to participate
Our animal studies were performed in accordance with Medical University of South Carolina (MUSC) Institutional Animal Care and Use Committee approved procedures.

Funding
This work was supported by MUSC Hollings Cancer Center Startup Fund, Hollings Cancer Center ACS IRG (YK), ASCO Conquer Cancer Foundation Career Development Award (YK), NIH/NIH HL103780 (YK), NCI P30CA138313-01S3 (YK and AK), NCI R01CA197792 (YK), R01CA173200 (AK), R01CA172495 (HC), and DOD W81XWH-15-1-0507 (HC). The funding agents had no roles in the design of the study, in the collection, analysis and interpretation of data, and in writing the manuscript.

Fig. 4 Pim1 regulates c-Kit gene translation. **a** Pim1 enhances the synthesis of new c-Kit protein. HEK 293 cells transfected with Fu-CRW-Ctl or Fu-CRW-Pim1 were treated with cycloheximide (CHX, 100 µg/ml) for 3 h. The cells were then labeled with <sup>35</sup>S methionine. Newly synthesized c-Kit was immunoprecipitated and separated by SDS-PAGE, and visualized by autoradiography (top panel). Aliquots of the cell lysates were run on SDS-PAGE and stained with Coomassie blue to be used for controlling the amount to protein loading (bottom panel). M: protein molecular weight marker. Data represent 2 independent experiments. **b** Pim1 kinase enhances c-Kit RNA incorporation in ribosome fractions. HEK 293 cells were transduced with control lentiviruses (Fu-Ctl) or Pim1-expressing lentiviruses (Fu-Pim1). Light and heavy ribosome fractions were collected for 17 fractions (0.5 ml/ fraction) by sucrose gradient centrifugation. The Levels of c-Kit mRNA and β-actin mRNA in the fractions were measured by semi-quantitative RT-PCR assays and the products were run on agarose gel. **c** Pim inhibitors down-regulated the phosphorylation of eIF4B Ser422. Molm-16 cells were treated with DMSO or pan-Pim inhibitors (SGI1776 at 7 µM or CX6258 4 µM) for 24 h. The cells were harvested and immunoblot analyses were performed. Data represent 3 independent experiments.
References

1. Ogawa M, Matsuzaki Y, Nishikawa S, Hayashi S, Kunisada T, Sudo T, Kina T, Nakauchi H, Nishikawa S. Expression and function of c-kit in hematopoietic progenitor cells. J Exp Med. 1991;174:63–71.

2. Noack K, Tan JC, Chu E, Chu TY, Ray P, Traktman P, Besmer P. Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus. W37, Ww, W41 and W. EMBO J. 1990;9:1805–13.

3. Kimura Y, Ding B, Imai N, Nolan DJ, Butler JM, Rafii S. c-Kit-mediated functional positioning of stem cells to their niches is essential for maintenance and regeneration of adult hematopoiesis. PLoS ONE. 2011;6:e26918.

4. Liang J, Wu YL, Chen BJ, Zhang W, Tanaka Y, Sugiyama Y. The c-kit receptor-mediated signal transduction and tumor-related diseases. Int J Biol Sci. 2013;9:435–43.

5. Wang C, Curtis JE, Geisler EN, McCulloch EA, Minden MD. The expression of the proto-oncogene C-kit in the blast cells of acute myeloblastic leukemia. Leukemia. 1989;3:699–702.

6. Ikeda H, Kanakura Y, Tamaki T, Kurisu A, Kitayama H, Ishikawa J, Kanayama Y, Yonezawa T, Tarui S, Griffin JD. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood. 1991;78:2962–8.

7. Bellone M, Svensson AM, Zaslav AL, Spitzer S, Golightly M, Celiker M, Hu Y, Ma Y, Ahmed T. Pediatric T-cell prolymphocytic leukemia with an isolated 12(p13) deletion and aberrant CD117 expression. Exp Hematol Oncol. 2012;1:7.

8. Yasuda H, Galli SJ, Geisler EN. Cloning and functional analysis of the mouse c-kit promoter. Biochem Biophys Res Commun. 1993;191:893–901.

9. Melotti P, Calabretta B. The transcription factors c-myb and GATA-2 act independently in the regulation of normal hematopoiesis. Proc Natl Acad Sci USA. 1996;93:5313–8.

10. Lin TY, Fenger J, Murahari S, Butler JM, Bear MD, Kulp SK, Wang D, Chen CS, Kisselev P, Melief C, Berns A. Cbl. Exp Cell Res. 2007;313:3935–42.

11. Sun J, Pedersen M, Bengtsson S, Ronnstrand L. Grb2 mediates negative regulation of stem cell factor receptor/c-Kit signaling by recruitment of Cbl. Exp Cell Res. 2007;313:3935–42.

12. Braut L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica. 2010;95:1004–15.

13. Cuyper HS, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W, van Wezenbeek P, Melief C, Berns A. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell. 1984;34:141–50.

14. Breuer ML, Cuyper HS, Berns A. Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas. EMBO J. 1989;8:743–8.

15. Mikkels H, Allen J, Knipscheer P, Remeijn L, Hart A, Vink E, Berns A. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet. 2002;32:153–9.

16. Mikkels H, Navijn M, Allen J, Brouwer C, Verhoeven E, Jonkers J, Berns A. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol. 2004;24:6104–15.

17. An N, Lin YW, Mahajan S, Kellner JN, Wang Y, Li Z, Kraft AS, Kang Y. Pim1 serine/threonine kinase regulates the number and functions of murine hematopoietic stem cells. Stem Cells. 2013;31:1202–12.

18. An N, Kraft AS, Kang Y. Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. J Hematol Oncol. 2013;6:12.

19. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183:1797–806.

20. Kalatzis D, Neel BG. Flow-cytometric phosphoprotein analysis reveals agonist and temporal differences in responses of murine hematopoietic stem/progenitor cells. PLoS ONE. 2008;3:e3776.

21. Song JH, Kraft AS. Pim kinase inhibitors sensitise prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. Cancer Res. 2012;72:294–303.

22. Leslie NR, O’Rey J, Bartholomew C, Harrison PR. An activating mutation in the kit receptor abolishes the stroma requirement for growth of EL4 thymic leukemia cells, but does not prevent their differentiation in response to erythropoietin. Blood. 1998;92:4798–807.

23. Cai H, Babic I, Wei X, Huang J, Witte ON. Invasive prostate carcinoma driven by c-src and androgen receptor synergy. Cancer Res. 2011;71:862–72.

24. Xin L, Ide H, Kim Y, Dubey P, Witte ON. In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme. Proc Natl Acad Sci USA. 2003;100(Suppl 1):11896–903.

25. Ventura Ferreira MS, Bergmann C, Bodensiek I, Peukert K, Abert J, Kramm R, Kachel P, Rath B, Rutten S, Knuchel R, et al. An engineered multi-component bone marrow niche for the recapitulation of hematopoiesis at ectopic transplantation sites. J Hematol Oncol. 2016;9:4.

26. Merrick WC, Hersold JO. Analysis of eukaryotic translation in purified and semipurified systems. Curr Protoc Cell Biol. 2001;Chapter 11: Unit 11.9.

doi:10.1002/0471143030cb11098.

27. Zemskova MY, Song JH, Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim family kinases control the activity against malignant mast cell lines via down-regulation of constitutively activated Kit. Blood. 2010;115:2417–25.

28. Cai H, Babic I, Wei X, Huang J, Witte ON. Invasive prostate carcinoma driven by c-src and androgen receptor synergy. Cancer Res. 2011;71:862–72.

29. Shahbazian D, Parsyan A, Petroulakis E, Hershey J, Sonenberg N. eIF4B enhances tumor growth of prostate cancer cells. Mol Cancer Res. 2013;11:2517–32.

30. Leskowitz S, Wysocki S, Melief C, Berns AS. Pim1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cancer cells. Cancer Biol Ther. 2009;8:846–53.

31. Zemskova MY, Song JH, Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cancer cells. Cancer Biol Ther. 2009;8:846–53.

32. Leskowitz S, Wysocki S, Melief C, Berns AS. Pim1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cancer cells. Cancer Biol Ther. 2009;8:846–53.

33. Zemskova MY, Song JH, Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cancer cells. Cancer Biol Ther. 2009;8:846–53.

34. Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, Pilorge S, Pellaton C, Ma Y, Ahmed T. Pediatric T-cell prolymphocytic leukemia with an isolated 12(p13) deletion and aberrant CD117 expression. Exp Hematol Oncol. 2012;1:e1500221.

35. Zemskova MY, Song JH, Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim family kinases control the activity against malignant mast cell lines via down-regulation of constitutively activated Kit. Blood. 2010;115:2417–25.

36. Leskowitz S, Wysocki S, Melief C, Berns AS. Pim1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cancer cells. Cancer Biol Ther. 2009;8:846–53.

37. Zemskova MY, Song JH, Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cancer cells. Cancer Biol Ther. 2009;8:846–53.

38. Leskowitz S, Wysocki S, Melief C, Berns AS. Pim1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cancer cells. Cancer Biol Ther. 2009;8:846–53.

39. Leskowitz S, Wysocki S, Melief C, Berns AS. Pim1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cancer cells. Cancer Biol Ther. 2009;8:846–53.